GeoVax to Showcase Mpox Vaccine Progress at Emerging Growth Conference

GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present at the Emerging Growth Conference on August 20, 2025. The presentation will focus on the company's GEO-MVA, a next-generation MVA-based Mpox/smallpox vaccine, and its development program. David Dodd, Chairman and CEO of GeoVax, will provide insights into the vaccine's progress and upcoming milestones, following favorable Scientific Advice from the European Medicines Agency that could expedite regulatory approval.

The conference offers a platform for GeoVax to highlight how its MVA platform and U.S.-based manufacturing capabilities are addressing vaccine supply diversification and pandemic readiness. Interested parties can register for the event here, with opportunities to submit questions in advance or during the live Q&A session. A replay will be available post-event on www.EmergingGrowth.com and the Emerging Growth YouTube channel.

GeoVax's efforts in developing vaccines for infectious diseases and therapies for cancer underscore its commitment to addressing critical health challenges. The company's advancements in vaccine technology and regulatory progress position it as a key player in global health security and biosecurity initiatives.